NEW MARKERS OF INFLAMMATION, ATHEROGENESIS AND METABOLIC DISTURBANCES IN MENOPAUSAL WOMEN EHUH 2 STUDY

Objective: Traditional risk factors can not completely explain higher cardiovascular (CV) morbidity and mortality in hypertensive menopausal women. The aim of this study was to investigate differences of novel biomarkers of inflammation, atherogenesis and metabolic disturbances between normotensive (NT) and hypertensive (AH) women in general population. Design and method: This cross-sectional study was part of the EH–UH 2 survey. Out of total of 2021 participants included by random selection from the general adult population, this study involved 622 menopausal women with AH (N=404) and NT (N=218). Participants completed a survey on CV morbidity, and fasting blood and urine samples were collected for various novel biomarkers of inflammation, atherogenesis and metabolic disturbances: neutrophils/lymphocytes, neutrophils/HDL, HOMA, triglycerides/blood glucose, triglycerides x BMI, monocytes/HDL, urate/creatinine (serum), cholesterol/HDL, Apo B/Apo A, WBC/Apo-AI, log (triglycerides/HDL), ln (triglycerides x blood glucose/2), blood glucose/HDL. Results: Compared to NT women, women with AH had elevated neutrophils/ HDL cholesterol (41.5 vs. 49.2), neutrophils/lymphocytes (6.59 vs. 5.23), triglycerides/HDL cholesterol (1.31 vs.1.07), glucose/HDL cholesterol (3.89 vs. 3.46), and product of multiplication of triglycerides and BMI (45-16 vs.39.43). There was no significant difference between monocytes/HDL cholesterol ratio between two groups. Analysis of a rate pressure product (RPP) showed that RPP was higher in a AH group than in NT women (10.78 vs 9.05) Conclusions: Compared to NT, women with AH have elevated several novel biomarkers of inflammation, atherogenesis and metabolic disturbances, as well as higher RPP which could contribute to higher CV risk. Further studies are needed to evaluate clinical value of these findings.